Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

    Research output: Contribution to journalArticle

    Abstract

    As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormone receptor measurements (and other patient characteristics) to long-term outcome can be assessed increasingly reliably. We report updated meta-analyses of the trials of 5 years of adjuvant tamoxifen. We undertook a collaborative meta-analysis of individual patient data from 20 trials (n=21 457) in early breast cancer of about 5 years of tamoxifen versus no adjuvant tamoxifen, with about 80% compliance. Recurrence and death rate ratios (RRs) were from log-rank analyses by allocated treatment.
    Original languageEnglish
    Pages (from-to)771-784
    Number of pages14
    JournalLancet
    Volume378
    Issue number9793
    Early online date29 Jul 2011
    DOIs
    Publication statusPublished - Aug 2011

    Keywords

    • breast cancer
    • hormone receptors
    • tamoxifen
    • randomised trials

    Fingerprint Dive into the research topics of 'Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials'. Together they form a unique fingerprint.

  • Cite this